Gadobenate dimeglumine–enhanced biliary imaging from the hepatobiliary phase can predict progression in patients with liver cirrhosis
- 3 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Radiology
- Vol. 31 (8), 5840-5850
- https://doi.org/10.1007/s00330-021-07702-6
Abstract
Objectives To determine the value of gadobenate dimeglumine (Gd-BOPTA)–enhanced biliary imaging from the hepatobiliary phase in predicting hepatic decompensation and insufficiency for patients with cirrhosis. Methods This single-center retrospective study included 270 patients who underwent Gd-BOPTA-enhanced magnetic resonance imaging. The relative enhancement ratios of the biliary system (REB) and liver parenchyma (REL) in patients with normal liver function without underlying chronic liver disease and three groups of patients with Child-Pugh A, Child-Pugh B, and Child-Pugh C disease were measured. After a mean follow-up of 38.5 ± 22.5 months, prognostic factors were evaluated using the Cox proportional hazards regression model. Receiver operating characteristic (ROC) curve analyses were performed to assess the capacity of the REB and REL to predict the development of hepatic decompensation and insufficiency. Results During the follow-up period, nine of 79 patients with Child-Pugh A disease developed hepatic decompensation. The REB was a significant predictive factor (hazard ratio (HR) = 0.40 (0.19–0.84); p = 0.016), but the REL showed no association with hepatic decompensation. Moreover, the areas under the ROC curves (AUCs) were 0.83 and 0.52 for the REB and REL, respectively. Thirty-eight of 207 patients with cirrhosis developed hepatic insufficiency. The REB was a significant predictive factor (HR = 0.24 (0.13–0.46); p < 0.0001), but the REL did not show statistically significant association with hepatic insufficiency. The AUCs were 0.82 and 0.57 for the REB and REL, respectively. Conclusions Gd-BOPTA-enhanced biliary imaging from the hepatobiliary phase was valuable in predicting hepatic decompensation and insufficiency for cirrhotic patients. Key Points • Gd-BOPTA-enhanced biliary imaging was a significant predictive factor for hepatic decompensation in patients with cirrhosis. • Gd-BOPTA-enhanced biliary imaging was a significant predictive factor for hepatic insufficiency in patients with cirrhosis. • Gd-BOPTA-enhanced biliary imaging showed superior predictive values for adverse clinical outcomes compared to liver parenchymal imaging at the hepatobiliary phase.Funding Information
- Academic promotion programme of Shandong First Medical University (2019QL023)
This publication has 41 references indexed in Scilit:
- Contemporary Epidemiology of Chronic Liver Disease and CirrhosisClinical Gastroenterology and Hepatology, 2019
- Clinical states of cirrhosis and competing risksJournal of Hepatology, 2018
- Quantitative Liver Function Analysis: Volumetric T1 Mapping with Fast Multisection B1Inhomogeneity Correction in Hepatocyte-specific Contrast-enhanced Liver MR ImagingRadiology, 2017
- Risk assessment of clinical outcomes in Asian patients with chronic hepatitis B using enhanced liver fibrosis testJournal of Hepatology, 2014
- Liver cirrhosisThe Lancet, 2014
- Liver Stiffness Is Associated With Risk of Decompensation, Liver Cancer, and Death in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysisClinical Gastroenterology and Hepatology, 2013
- The rate of decompensation and clinical progression of disease in people with cirrhosis: a cohort studyAlimentary Pharmacology & Therapeutics, 2010
- Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosisJournal of Hepatology, 2009
- Limitations of conventionally derived chronic liver disease mortality rates: Results of a comprehensive assessmentJournal of Hepatology, 2007
- Serum markers detect the presence of liver fibrosis: A cohort studyGastroenterology, 2004